Intracranial CAR-T cell delivery in glioblastoma patients
- PMID: 38777680
- DOI: 10.1016/j.trecan.2024.05.002
Intracranial CAR-T cell delivery in glioblastoma patients
Abstract
Chimeric antigen receptor (CAR)-T cell therapy is emerging as a promising approach for improving outcomes in high-grade glioma. Here, we highlight three recent studies that reported safety and feasibility of intracranial CAR-T cell administration in patients with glioblastoma (GBM) as well as preliminary evidence of potential responses, supporting further investigations of this approach.
Keywords: CAR-T cells; clinical trial; glioblastoma; immunotherapy.
Published by Elsevier Inc.
Conflict of interest statement
Declaration of interests No interests are declared.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical